Find a Cancer Provider

Are you a referring physician?
within
I am searching for a
Reset Form
Elise A. Chong, MD

Elise A. Chong, MD Physician

Assistant Professor of Medicine at the Hospital of the University of Pennsylvania

Dr. Chong is employed by Penn Medicine.

Clinical Specialties

Specialty:

  • Hematology

Programs & Centers:

Board Certification:

  • Internal Medicine, 2016

Clinical Expertise:

  • Acute Lymphocytic Leukemia
  • Acute Myelogenous Leukemia
  • Acute Promyelocytic Leukemia
  • Adult T-Cell Leukemia
  • Adult T-Cell Lymphoma
  • AIDS Related Malignancies
  • Amyloidosis
  • Anaplastic Large Cell Lymphoma
  • Blood Cancer
  • Bone Marrow Biopsy
  • Bone Marrow Failure Syndromes
  • Burkitt Lymphoma
  • Cancer During Pregnancy
  • Car-T Cell Therapy
  • Castleman Disease
  • Chronic Lymphocytic Leukemia
  • Chronic Myelocytic Leukemia
  • Chronic Myelomonocytic Leukemia
  • CNS Lymphoma
  • Cutaneous B Cell Lymphoma
  • Cutaneous Lymphoma
  • Cutaneous T-Cell Lymphoma
  • Eosinophilic Granuloma
  • Erdheim-Chester Disease
  • Essential Thrombocytosis
  • Graft Versus Host Disease
  • Gray Zone Lymphoma
  • Hairy Cell Leukemia
  • Hematologic Malignancies
  • Histiocytosis
  • HIV Lymphoma
  • HIV Malignancies
  • Hodgkin Lymphoma
  • Immunotherapy
  • Intraocular Lymphoma
  • Large Granular Lymphocytic Leukemia
  • Leukemia
  • Light Chain Disorders
  • Lymphoma
  • Lymphoma During Pregnancy
  • Lymphoma Genomics
  • Lymphoma of Bone
  • Mantle Zone Lymphoma
  • Marginal Zone Lymphoma
  • Mediastinal Lymphoma
  • Monoclonal Gammopathy of Undetermined Significance
  • Mucosa-Associated Lymphoid Tissue Lymphoma
  • Multiple Myeloma
  • Myelodysplastic Syndromes (MDS)
  • Myeloproliferative Neoplasms (MPN)
  • Non-Hodgkin Lymphoma
  • Pelvic Malignancy During Pregnancy
  • Peripheral T-Cell Lymphoma
  • Plasma Cell Dyscrasia
  • POEMS Syndrome
  • Polycythemia
  • Primary Myelofibrosis
  • Prolymphocytic Leukemia
  • Refractory Anemia With Excess Blasts
  • Sezary Syndrome
  • Small Lymphocytic Lymphoma
  • Transformed Lymphoma
  • Waldenstrom Macroglobulinemia (WM)
Show All Expertise

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • eLAP Services
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Homestead Smart Health Plans
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • OPR Medicare
  • OPR New Jersey Medicaid
  • OPR Pennsylvania Medicaid
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Provider Partners Health Plan
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: University of Pennsylvania School of Medicine
Residency: Hospital of the University of Pennsylvania
Fellowship: Hospital of the University of Pennsylvania

Memberships

American Association for Cancer Research, National American Society of Clinical Oncology, National American Society of Hematology, National Society for Immunotherapy of Cancer, National

Hospital Affiliation

Dr. Chong is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.

Research

Selected Publications:

Farhan A, Chong EA, Schuster SJ, Strelec L, Nasta SD, Landsburg D, Svoboda J.: Bexarotene in Patients With Peripheral T-cell Lymphomas: Results of a Retrospective Study. Clin Lymphoma Myeloma Leuk 19 (2): 109-115,2019.

Chong EA, Svoboda J, Nasta SD, Landsburg DL, Winchell N, Napier E, Mato AR, Melenhorst JJ, Ruella M, Lacey SM, June CH, Schuster SJ.: Sequential Anti CD 19 Directed Chimeric Antigen Receptor Modified T Cell Therapy (CART19) and PD 1 Blockade with Pembrolizumab in Patients with Relapsed or Refractory B Cell Non Hodgkin Lymphomas. American Society of Hematology Annual Meeting, San Diego, CA : 2018.

Chong EA, Levine BL, Grupp SA, Davis M, Siegel DL, Maude SL, Gladney WL, Frey NV, Porter DL, June CH, Schuster SJ.: CD 19 Directed CAR T Cell (CTL019) Product Viability and Clinical Outcomes in Non Hodgkin Lymphomas and B Cell Acute Lymphoblastic Leukemia. American Society of Hematology Annual Meeting, San Diego, CA : 2018.

Mato AR, Dorsey C, Chatburn ET, Geoghegan J, Schuster SJ, Svoboda J, Becker PS, Chong EA, Nasta SD, Landsburg DJ, Kennard K, Luning-Prak E, Tsao PS, Hughes ME, Purdom M, Paskalis D, Sportelli P, Miskin HP, Weiss MS, Shadman M.: Phase I/II Study of Pembrolizumab in Combination with TG-1101 (ublituximab) and TGR-1202 (umbralisib) in Patients with Relapsed Refractory CLL or Richter’s Transformation of CLL. American Society of Hematology Annual Meeting, Atlanta, GA : 2017.

Chong EA, Napier E, Svoboda J, Nasta SD, Mato AR, Landsburg DL, Schuster SJ.: Long term outcomes of lenalidomide and rituximab in rituximab resistance patients with indolent B cell and mantle cell lymphomas. American Society of Hematology Annual Meeting, Atlanta, GA : 2017.

Chong EA, Melenhorst JJ, Svoboda J, Nasta SD, Landsburg DJ, Mato AR, Tian L, Parakandi H, Lacey SF, June CF, Schuster SJ.: Phase I/II Study of Pembrolizumab for Progressive Diffuse Large B Cell Lymphoma after Anti-CD19 Directed Chimeric Antigen Receptor Modified T Cell Therapy. American Society of Hematology Annual Meeting, Atlanta, GA : 2017.

Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, June CH.: Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N Engl J Med 377 (26): 2545-2554,2017.

Chong EA, Melenhorst JJ, Lacey SF, Ambrose DE, Gonzalez V, Levine BL, June CH, Schuster SJ.: PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood 129 (8): 1039-1041,2017.

Schuster SJ, Svoboda J. Nasta S, Chong EA, Porter DL, Landsburg DJ, Mato AR, Bhoj VG, Milone M, Lacey SF, Strelec LE, Zhou AY, Melenhorst JJ, Chew A, Hasskarl J, Wasik MA, Marcucci K, Zheng Z, Levine B, June CH.: Treatment with chimeric antigen receptor modified T cells directed against CD 19 (CTL019) results in durable remissions in patients with relapsed or refractory diffuse large B cell lymphomas of germinal center and non-germinal center origin, "Double Hit" diffuse large B cell lymphomas, and transformed follicular to diffuse large B cell lymphomas. American Society of Hematology Meeting, San Diego, CA : 2016.

Svoboda J, Strelec LE, Landsburg DJ, Nasta SD, Mato AR, Hwang W, Nagle SJ, Chong EA, Garrett S, Waite TS, Napier E, Schuster SJ.: Lenalidomide Maintenance after Autologous Stem Cell Transplant in Patients with High-Risk Relapsed/Refractory Lymphomas Is Feasible and Compares Favorably to Historical Controls: Results of a Phase I/II Trial. American Society of Hematology Meeting, San Diego, CA : 2016.

Academic Contact Info

Perelman Center for Advanced Medicine
3400 Civic Center Blvd
12th Floor, South Pavilion

Philadelphia, PA 19104
Patient appointments: 800-789-7366 (PENN)